News | January 06, 2014

Studies Assessing Stentys in Indications Outside of Heart Attacks Presented at TCT 2013

stentys self-apposing stent clinical trial study TCT 2013 cath lab

January 6, 2014 — Stentys, developer of the world's first self-apposing stent to treat acute myocardial infarction (AMI), announced new data in indications outside of myocardial infarction. Results from the OPEN II study and a series from the Amsterdam Medical Center were presented during the TCT conference (TCT 2013) in San Francisco.
 
OPEN II is a prospective, single-arm trial that enrolled 217 patients treated for chest pain due to a narrowing at a coronary artery bifurcation with the Stentys paclitaxel-eluting stent in 21 hospitals in six European countries. The primary endpoint of MACE (composite of cardiac death, myocardial infarction, emergent bypass surgery and target lesion revascularization) at six months was 10.1 percent for the whole study group, with a rate of 6.9 percent in patients with simple lesions. Christoph Naber, M.D., Ph.D., Contilia Heart and Vascular Center, Essen, Germany, and principal investigator of the study, presented the results.
 
“This large study in a highly complex group of patients with challenging lesions confirms that the Stentys stent can be used in routine practice and leads to very good results compared to those published historically,” said Naber.
 
Huangling Lu, M.D., from Amsterdam Medical Center, Netherlands, also presented a series of 87 patients treated with Stentys at her institution. This series enrolled primarily patients with atypical anatomy: 53 percent had aneurysmatic or ectactic vessels, 31 percent had tapered vessels, 23 percent had large vessels (above 4.5 mm) and 10 percent had bypass grafts. At 12 months, the MACE rate was 4.7 percent.
 
“The Self-Apposing stent is the only available product that can conform to complex, non-cylindrical vessel anatomy, as detailed on its recently extended CE mark label,” said Gonzague Issenmann, CEO and co-founder, Stentys.
 
The Stentys Self-Apposing stent is engineered to solve the dilemma of artery diameter discrepancy. Its flexible, self-expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel.
 
For more information: www.stentys.com

Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now